World of DTC Marketing

JUNE 1, 2021

SUMMARY: The FDA is coming under intense pressure to approve Biogen’s Alzheimer’s drug, but Aaron S. Kesselheim, a professor of medicine at Harvard Medical School via the Washington Post , says “the worst thing for people with Alzheimer’s would be to put out a product that doesn’t work.”

Side effects 187

Side effects FDA Patients Doctors 187

World of DTC Marketing

SEPTEMBER 24, 2021

Then, against the advisory panel’s advice, Aduhelm was approved, but insiders within the industry criticized both the FDA and Biogen weren’t sold on the drug or its price tag. Many doctors also became upset at the idea of telling Alzheimer’s patients that the drug didn’t work.

Insurance 222

Insurance Pharma Doctors Physicians 222

World of DTC Marketing

JUNE 23, 2021

Not to mention the $56,000 annual price tag. So far, no method of breaking down/removing amyloid plaques has been shown to prevent symptomatic Alzheimer’s disease in humans. Aduhelm joins a group of drugs that potentially leave patients worse off and much poorer for it. I, therefore, find the FDA’s decision to be puzzling.

FDA 218

FDA Side effects Physicians Patients 218